Skip to content
Clinical Trials – home
Verifiedinfo

University Hospital Consorziale Policlinico

Italy Piazzale Giulio Cesare 11, 70124 Bari, Italy

  • 18 trials recruiting
  • Plasma cell myeloma · Acute myeloid leukaemia · Myelodysplastic syndrome
  • Adults and children

About Specializations

University Hospital Consorziale Policlinico in Bari, Italy specialises in clinical trials of conditions such as Plasma cell myeloma, Acute myeloid leukaemia, Myelodysplastic syndrome, Acute lymphocytic leukaemia, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology and Hematology

At University Hospital Consorziale Policlinico in Bari, clinical research in neoplasms focuses on improving outcomes for people with ER+/HER2- early breast cancer and newly diagnosed Philadelphia-negative B-cell precursor acute lymphoblastic leukemia. These studies are designed to test new treatment approaches, strengthen long-term disease control, and compare how well different therapies can prevent recurrence or improve survival.

  • ER+/HER2- early breast cancer: evaluating whether extended endocrine-based treatment can better prevent cancer recurrence.
  • Philadelphia-negative B-cell precursor acute lymphoblastic leukemia: assessing a new treatment strategy for older adults to improve survival and disease control.

This research reflects a strong focus on treatment effectiveness and better long-term outcomes in common and complex blood and breast cancers.

Immune System and Inflammatory Diseases

The site also supports studies in immune system diseases and immune system phenomena, with research centered on Langerhans cell histiocytosis and idiopathic inflammatory myopathies such as polymyositis and dermatomyositis. These trials aim to reduce relapses, limit lasting complications, and evaluate whether new therapies can better control inflammation and improve disease activity.

  • Langerhans cell histiocytosis: studying ways to reduce mortality, prevent reactivations, and improve long-term control of the disease.
  • Polymyositis and dermatomyositis: testing a therapy intended to improve disease activity in adults with inflammatory muscle disease.

This area highlights the hospital’s interest in both rare immune disorders and chronic inflammatory conditions where better symptom control and fewer flare-ups are key goals.

Eye Diseases

Research in eye diseases at the Palazzo Istituti Biologici Sezione di Igiene includes a study of macular edema secondary to retinal vein occlusion. The trial is focused on assessing whether a different treatment schedule can preserve vision as effectively while maintaining safety and convenience for patients with retinal swelling.

  • Macular edema secondary to retinal vein occlusion: evaluating a therapy aimed at improving visual outcomes and controlling retinal swelling.

This work is centered on protecting sight and improving treatment effectiveness for a common cause of vision loss.

Musculoskeletal and Neural Conditions

Clinical trials in musculoskeletal diseases and related physiological phenomena address inflammatory muscle disorders that can affect strength, mobility, and daily function. At this hospital, the research is aimed at improving disease control, reducing disability, and supporting better quality of life for patients living with chronic muscle inflammation.

  • Polymyositis: investigating a treatment approach to better control inflammation and improve disease activity.
  • Dermatomyositis: studying ways to ease symptoms and improve overall disease management.

The focus here is on therapies that may offer more reliable relief for patients with challenging autoimmune muscle diseases.

Infectious Disease Prevention

The site contributes to research on prevention of RSV, an important area in immune system and public health research. This trial is designed to evaluate whether a preventive approach can lower the risk of serious respiratory illness in healthy infants, with attention to both protection and safety.

  • Prevention of RSV: testing a strategy to reduce medically attended lower respiratory infections in infants.

This work supports efforts to protect young children from respiratory syncytial virus and its complications.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Piazzale Giulio Cesare 1170124 BariItaly
Recruiting now
18 trials
Conditions studied
58
Partner status
Verified

More sites in BariItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

70 clinical trials

Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Ryvu Therapeutics S.A.
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Asparaginase
  • Sponsor:Amgen Inc.
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Fondazione GONO G.I.
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Glaxosmithkline Research & Development Limited
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Equine Immunoglobulin F(Ab')2 Fragments Targeting Shiga Toxin
  • Sponsor:Chemo Research S.L.
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:The University Of Birmingham
Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Glaxosmithkline Research & Development Limited
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Cyclophosphamide
  • Sponsor:Universitaetsklinikum Muenster AöR
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.